Integer 8K 2017 by Quarter and Total Year - 5 periods | ITGR 30 Jul 18

Exhibit 99.1

LOGO

HISTORICAL FINANCIAL INFORMATION

2017 by Quarter and Total Year - 5 periods

2018 by 1st Quarter - 1 period

GENERAL

∎

Non-GAAP Financial Information

∎

Discontinued Operations Reporting

∎

Important Note Regarding Financial Statements

∎

Assumptions

HISTORICAL FINANCIAL INFORMATION PRESENTED

Continuing Operations Statements and GAAP toNon-GAAP Reconciliations

∎

GAAP Statements of Continuing Operations Trend

∎

NON-GAAP Statements of Continuing Operations Trend

∎

Sales from Continuing Operations Trend

∎

Income from Continuing Operations Reconciliation Trend

∎

EBITDA from Continuing Operations Reconciliation Trend

Bridges To Previously Reported

∎

GAAP Statement of Operations Detail (6 periods)

∎

Statement of Continuing Operations GAAP toNON-GAAP Reconciliation Detail (6 periods)

∎

Sales GAAP toNon-GAAP Reconciliation (GAAP &Non-GAAP) (6 periods)

∎

Net Income GAAP toNon-GAAP Reconciliation (6 periods)

∎

EBITDA GAAP toNon-GAAP Reconciliation (6 periods)

Page 1 of 39

LOGO

NON-GAAP FINANCIAL INFORMATION

The Company usesnon-GAAP financial measures, including the measures provided in this presentation, to describe its operating results as well as the effect of the divestiture of the AS&O business which closed on July 2, 2018. Our management team believes that the presentation of these measures provides useful information to investors and that these measures may assist investors in evaluating the Company’s operations period over period. Investors should consider thesenon-GAAP measures only as a supplement to, not as a substitute for or as superior to, measures of financial performance prepared in accordance with GAAP.

Non-GAAP measures include the net impact of the Long-term Supply Agreements (“LSA”) entered into between the Company and Viant (formerly MedPlast LLC) as of the closing of the divestiture of the Advanced Surgical and Orthopedic product lines. These long term supply agreements govern the sale of products supplied by Viant to the Company for further resale to customers and by the Company to Viant for further resale to customers.

Page 2 of 39

DISCONTINUED OPERATIONS REPORTING

For disposal transactions, a component of an entity that is anticipated to be sold in the future is reported in discontinued operations after it meets the criteria forheld-for-sale classification, and if the disposition represents a strategic shift that has (or will have) a major effect on the entity’s operations and financial results. Integer evaluated the quantitative and qualitative factors related to the sale of the AS&O business and concluded that it met theheld-for-sale criteria and discontinued operations presentation. The AS&O business financial results are reported within Discontinued Operations in these financial statements.

Interest expense from discontinued operations was computed using the actual weighted average interest rate on the respective debt for the period presented assuming $548 million of cash proceeds from the AS&O sale were used to first redeem all of the Company’s outstanding 9.125% Senior Notes due 2023, second to repay the outstanding balance of the Company’s revolving credit loans outstanding during the period presented, and third, to use the remaining net cash proceeds to prepay the Company’s outstanding Term B loans.

IMPORTANT NOTE REGARDING PRO FORMA FINANCIAL STATEMENTS

These financial statements will not agree to the pro forma financial statements filed by the Company on Form8-K on July 9, 2018, in connection with the AS&O divestiture as those statements adjust for the pro forma effects in accordance with Article 11 of RegulationS-X. These statements were prepared using the assumptions described herein under the caption Assumptions.

The following financial statements are based on information currently available and have been prepared using certain assumptions and estimates. These unaudited financial statements are intended for informational purposes only, and do not purport to represent what Integer’s financial position and results of operations actually would have been had the AS&O divestiture occurred on the dates indicated, or to project Integer’s financial position or results of operations for any future date or period.

Page 3 of 39

ASSUMPTIONS

∎

The following slides present results as if the Integer divestiture of the AS&O business occurred at the beginning of Fiscal Year 2017.

∎

Income tax provision (benefit) for adjusted amounts were computed using the applicable statutory income tax rates in effect in the respective tax jurisdications during the periods presented. These rates do not reflect our effective tax rate, which include other items and may be significantly different than the rates assumed for purposes of preparing the adjusted financial statements for a variety of factors.

∎

Adjusted amountsdo not reflect the impact of the transition services agreement entered into with Viant to provide certain corporate services (including accounting, payroll, and information technology services) for a period of up to one year from the date of the closing to facilitate an orderly transfer of business operations. Viant will pay Integer for these services, which payments will vary in amount and length of time as specified in the transition services agreement. As there is no continuing impact on Integer’s results of operations from these transition services, no adjustments were made to the consolidated statements of operations set forth herein.

Page 4 of 39

GAAP STATEMENTS OF CONTINUING OPERATIONS

SUMMARY


	2017													2018
	Q1		Q2		Q3			Q4			FY			Q1


Sales	$	266,736	$	280,916	$	286,168		$	302,260		$	1,136,080		$	292,426
Cost of sales		184,708		191,741		196,982			208,639			782,070			208,894


Gross profit		82,028		89,175		89,186			93,621			354,010			83,532
Operating expenses:
Selling, general and administrative expenses		34,794		35,146		35,064			38,069			143,073			36,429
Research, development and engineering costs		11,637		11,240		12,227			13,746			48,850			13,276
Other operating expenses		11,694		6,727		6,069			11,948			36,438			3,784

Total operating expenses		58,125		53,113		53,360			63,763			228,361			53,489
Operating income		23,903		36,062		35,826			29,858			125,649			30,043
Interest expense		18,367		15,058		15,808			14,739			63,972			15,595
(Gain) loss on cost and equity investments, net		398		4,427		(1,906	)		(1,354	)		1,565			(4,970	)
Other loss, net		1,401		6,763		2,490			199			10,853			960

Income before taxes		3,737		9,814		19,434			16,274			49,259			18,458
Provision (benefit) for income taxes		789		255		(448	)		(38,424	)		(37,828	)		5,374

Income from continuing operations	$	2,948	$	9,559	$	19,882		$	54,698		$	87,087		$	13,084


Basic earnings per share	$	0.10	$	0.31	$	0.63		$	1.73		$	2.77		$	0.41
Diluted earnings per share	$	0.09	$	0.30	$	0.62		$	1.69		$	2.72		$	0.40

Page 5 of 39

NON-GAAP STATEMENTS OF CONTINUING OPERATIONS

SUMMARY


	2017										2018
	Q1		Q2		Q3		Q4		FY		Q1



Sales	$	265,256	$	280,242	$	284,564	$	300,692	$	1,130,754	$	291,731
Cost of sales		182,648		190,062		195,042		206,781		774,533		207,319

Gross profit		82,608		90,180		89,522		93,911		356,221		84,412
Gross margin		31%		32%		31%		31%		32%		29%
Operating expenses:
Selling, general and administrative		28,205		27,981		27,107		30,565		113,858		29,210
SG&A as a % of sales		11%		10%		10%		10%		43%		11%
Research, development and engineering		11,501		11,104		12,090		13,610		48,305		13,237
RD&E as a % of sales		4%		4%		4%		5%		18%		5%
Other operating expenses		-		-		-		-		-		-

Total operating expenses		39,706		39,085		39,197		44,175		162,163		42,447
Operating income		42,902		51,095		50,325		49,736		194,058		41,965
Operating margin		16%		18%		18%		17%		73%		16%
Interest expense		16,808		14,123		15,030		14,487		60,448		14,538
Loss on cost and equity investments, net		-		-		-		-		-		-
Other (income) loss, net		1,401		6,763		2,490		199		10,853		960

Income (loss) before taxes		24,693		30,209		32,805		35,050		122,757		26,467
Provision for income taxes		7,333		6,542		3,385		6,384		23,644		6,048
Effective tax rate		30%		22%		10%		18%		19%		23%

Income from continuing operations	$	17,360	$	23,667	$	29,420	$	28,666	$	99,113	$	20,419


Diluted earnings per share	$	0.55	$	0.74	$	0.91	$	0.89	$	3.09	$	0.63

Page 6 of 39

SALES FROM CONTINUING OPERATIONS

SUMMARY


	2017										2018
	Q1		Q2		Q3		Q4		FY		Q1

GAAP

Medical
Cardio & Vascular	$	123,484	$	130,718	$	137,712	$	138,917	$	530,831	$	136,863
Cardiac & Neuromodulation		103,755		106,173		101,612		116,735		428,275		108,910
Advanced Surgical, Orthopedics & Portable Medical		28,151		28,282		31,715		31,858		120,006		33,941

Total Medical		255,390		265,173		271,039		287,510		1,079,112		279,714
Non-Medical		11,346		15,743		15,129		14,750		56,968		12,712

Total sales	$	266,736	$	280,916	$	286,168	$	302,260	$	1,136,080	$	292,426


NON-GAAP

Medical
Cardio & Vascular	$	123,486	$	130,717	$	137,696	$	138,905	$	530,804	$	136,852
Cardiac & Neuromodulation		103,753		106,173		101,612		116,735		428,273		108,910
Advanced Surgical, Orthopedics & Portable Medical		26,671		27,609		30,127		30,302		114,709		33,257

Total Medical		253,910		264,499		269,435		285,942		1,073,786		279,019
Non-Medical		11,346		15,743		15,129		14,750		56,968		12,712

Total sales	$	265,256	$	280,242	$	284,564	$	300,692	$	1,130,754	$	291,731

Page 7 of 39

INCOME FROM CONTINUING OPERATIONS

GAAP TONON-GAAP RECONCILIATION

SUMMARY


	2017															2018
	Q1			Q2			Q3			Q4			FY			Q1

Income from continuing operations (GAAP)	$	2,948		$	9,559		$	19,882		$	54,698		$	87,087		$	13,084
Adjustments:
Amortization of intangibles		7,018			7,084			7,103			7,117			28,322			8,397
Depreciation on held for sale assets		-			-			-			-			-			-
IP related litigation (SG&A)		245			595			1,128			876			2,844			254
Strategic reorganization and alignment (OOE)		-			-			-			3,829			3,829			1,627
Manufacturing alignment to support growth (OOE)		-			-			-			-			-			369
Consolidation and optimization expenses (OOE)		1,867			2,028			2,630			3,733			10,258			455
Acquisition and integration expenses (OOE)		3,133			2,037			1,106			926			7,202			-
Asset dispositions, severance and other (OOE)		2,928			670			546			356			4,500			470
(Gain) loss on cost/equity method investments		259			2,877			(1,239	)		(880	)		1,017			(3,926	)
Loss on extinguishment of debt		1,013			608			506			164			2,291			835
LSA adjustments		(2,051	)		(1,791	)		(2,242	)		(2,347	)		(8,431	)		(2,240	)
Tax adjustments		-			-			-			(39,806	)		(39,806	)		1,094

Adjusted income from continuing operations(Non-GAAP)	$	17,360		$	23,667		$	29,420		$	28,666		$	99,113		$	20,419


Diluted earnings per share	$	0.55		$	0.74		$	0.91		$	0.89		$	3.09		$	0.63

Page 8 of 39

EBITDA FROM CONTINUING OPERATIONS

GAAP TONON-GAAP RECONCILIATION

SUMMARY


	2017															2018
*EBITDA and Adjusted EBITDA Reconciliation*	Q1			Q2			Q3			Q4			FY			Q1

Income from continuing operations (GAAP)	$	2,948		$	9,559		$	19,882		$	54,698		$	87,087		$	13,084
Adjustments:
Interest expense		18,367			15,058			15,808			14,739			63,972			15,595
Provision (benefit) for income taxes		789			255			(448	)		(38,424	)		(37,828	)		5,374
Depreciation		9,370			9,358			9,534			9,815			38,077			9,963
Amortization		10,083			10,147			10,145			10,193			40,568			10,653
EBITDA from continuing operations		41,557			44,377			54,921			51,021			191,876			54,669
IP related litigation		377			915			1,735			1,348			4,375			321
Stock-based compensation (excluding OOE)		2,173			2,902			2,041			4,167			11,283			2,979
Strategic reorganization and alignment		-			-			-			5,891			5,891			2,054
Manufacturing alignment to support growth		-			-			-			-			-			513
Consolidation and optimization expenses		2,347			2,729			2,979			4,880			12,803			575
Acquisition and integration expenses		4,820			2,970			2,267			813			10,870			-
Asset dispositions, severance and other		4,527			1,028			823			364			6,874			642
Non-cash (gain) loss on cost/equity method investments		398			4,427			(992	)		(868	)		2,965			(4,970	)
LSA adjustments		(3,155	)		(2,756	)		(3,450	)		(3,611	)		(12,972	)		(2,836	)
Adjusted EBITDA from continuing operations(Non-GAAP)	$	53,044		$	56,592		$	60,324		$	64,005		$	233,965		$	53,947

Page 9 of 39

GAAP STATEMENTS OF OPERATIONS

2017 Q1


	(a)			LESS:
	Total			Discontinued			Continuing
	Operations			Operations			Operations

Sales	$	345,413		$	78,677		$	266,736
Cost of sales		254,187			69,479			184,708

Gross profit		91,226			9,198			82,028
Operating expenses:
Selling, general and administrative expenses		39,499			4,705			34,794
Research, development and engineering costs		13,411			1,774			11,637
Other operating expenses		11,771			77			11,694

Total operating expenses		64,681			6,556			58,125
Operating income		26,545			2,642			23,903
Interest expense		28,893			10,526			18,367
Loss on cost and equity investments, net		398			-			398
Other loss, net		1,449			48			1,401

Income (loss) before taxes		(4,195	)		(7,932	)		3,737
Provision (benefit) for income taxes		144			(645	)		789

Net loss (income)	$	(4,339	)	$	(7,287	)	$	2,948


Basic earnings (loss) per share	$	(0.14	)		(0.23	)	$	0.10
Diluted earnings (loss) per share	$	(0.14	)		(0.23	)	$	0.09

Weighted average shares outstanding - Basic		31,016			31,016			31,016
Weighted average shares outstanding - Diluted		31,016			31,685			31,685

(a)

As previously reported in SEC filings prior to July 2018.

Page 10 of 39

GAAP STATEMENTS OF OPERATIONS

2017 Q2


	(a)		LESS:
	Total		Discontinued			Continuing
	Operations		Operations			Operations

Sales	$	362,719	$	81,803		$	280,916
Cost of sales		263,447		71,706			191,741

Gross profit		99,272		10,097			89,175
Operating expenses:
Selling, general and administrative expenses		39,724		4,578			35,146
Research, development and engineering costs		12,889		1,649			11,240
Other operating expenses		6,920		193			6,727

Total operating expenses		59,533		6,420			53,113
Operating income		39,739		3,677			36,062
Interest expense		25,647		10,589			15,058
Loss on cost and equity investments, net		4,427		-			4,427
Other (income) loss, net		5,549		(1,214	)		6,763

Income (loss) before taxes		4,116		(5,698	)		9,814
Provision for income taxes		1,126		871			255

Net income (loss)	$	2,990	$	(6,569	)	$	9,559


Basic earnings (loss) per share	$	0.10		(0.21	)	$	0.31
Diluted earnings (loss) per share	$	0.09		(0.21	)	$	0.30

Weighted average shares outstanding - Basic		31,302		31,302			31,302
Weighted average shares outstanding - Diluted		31,982		31,982			31,982

(a)

As previously reported in SEC filings prior to July 2018.

Page 11 of 39

GAAP STATEMENTS OF OPERATIONS

2017 Q3


	(a)			LESS:
	Total			Discontinued			Continuing
	Operations			Operations			Operations

Sales	$	363,308		$	77,140		$	286,168
Cost of sales		265,073			68,091			196,982

Gross profit		98,235			9,049			89,186
Operating expenses:
Selling, general and administrative expenses		39,733			4,669			35,064
Research, development and engineering costs		13,607			1,380			12,227
Other operating expenses		6,264			195			6,069

Total operating expenses		59,604			6,244			53,360
Operating income		38,631			2,805			35,826
Interest expense		26,485			10,677			15,808
Gain on cost and equity investments, net		(1,906	)		-			(1,906	)
Other (income) loss, net		2,062			(428	)		2,490

Income (loss) before taxes		11,990			(7,444	)		19,434
Benefit for income taxes		(1,700	)		(1,252	)		(448	)

Net income (loss)	$	13,690		$	(6,192	)	$	19,882


Basic earnings (loss) per share	$	0.43			(0.20	)	$	0.63
Diluted earnings (loss) per share	$	0.43			(0.19	)	$	0.62

Weighted average shares outstanding - Basic		31,594			31,594			31,594
Weighted average shares outstanding - Diluted		32,173			32,173			32,173

(a)

As previously reported in SEC filings prior to July 2018.

Page 12 of 39

GAAP STATEMENTS OF OPERATIONS

2017 Q4


	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Sales	$	390,481		$	88,221		$	302,260
Cost of sales		285,663			77,024			208,639

Gross profit		104,818			11,197			93,621
Operating expenses:
Selling, general and administrative expenses		42,617			4,548			38,069
Research, development and engineering costs		15,340			1,594			13,746
Other operating expenses		12,337			389			11,948

Total operating expenses		70,294			6,531			63,763
Operating income		34,524			4,666			29,858
Interest expense		25,435			10,696			14,739
Gain on cost and equity investments, net		(1,354	)		-			(1,354	)
Other loss, net		527			328			199

Income (loss) before taxes		9,916			(6,358	)		16,274
Benefit for income taxes		(44,422	)		(5,998	)		(38,424	)

Net income (loss)	$	54,338		$	(360	)	$	54,698


Basic earnings (loss) per share	$	1.71			(0.01	)	$	1.73
Diluted earnings (loss) per share	$	1.68			(0.01	)	$	1.69

Weighted average shares outstanding - Basic		31,698			31,698			31,698
Weighted average shares outstanding - Diluted		32,383			32,383			32,383

(a)

As previously reported in SEC filings prior to July 2018.

Page 13 of 39

GAAP STATEMENTS OF OPERATIONS

2017 FISCAL YEAR


	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Sales	$	1,461,921		$	325,841		$	1,136,080
Cost of sales		1,068,370			286,300			782,070

Gross profit		393,551			39,541			354,010
Operating expenses:
Selling, general and administrative expenses		161,573			18,500			143,073
Research, development and engineering costs		55,247			6,397			48,850
Other operating expenses		37,292			854			36,438

Total operating expenses		254,112			25,751			228,361
Operating income		139,439			13,790			125,649
Interest expense		106,460			42,488			63,972
Loss on cost and equity investments, net		1,565			-			1,565
Other (income) loss, net		9,587			(1,266	)		10,853

Income (loss) before taxes		21,827			(27,432	)		49,259
Benefit for income taxes		(44,852	)		(7,024	)		(37,828	)

Net income (loss)	$	66,679		$	(20,408	)	$	87,087


Basic earnings (loss) per share	$	2.12			(0.65	)	$	2.77
Diluted earnings (loss) per share	$	2.09			(0.64	)	$	2.72

Weighted average shares outstanding - Basic		31,402			31,402			31,402
Weighted average shares outstanding - Diluted		31,888			32,056			32,056

(a)

As previously reported in SEC filings prior to July 2018.

Page 14 of 39

GAAP STATEMENTS OF OPERATIONS

2018 Q1


	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Sales	$	381,745		$	89,319		$	292,426
Cost of sales		285,975			77,081			208,894

Gross profit		95,770			12,238			83,532
Operating expenses:
Selling, general and administrative expenses		41,238			4,809			36,429
Research, development and engineering costs		14,538			1,262			13,276
Other operating expenses		5,277			1,493			3,784

Total operating expenses		61,053			7,564			53,489
Operating income		34,717			4,674			30,043
Interest expense		26,445			10,850			15,595
Gain on cost and equity investments, net		(4,970	)		-			(4,970	)
Other loss, net		1,033			73			960

Income (loss) before taxes		12,209			(6,249	)		18,458
Provision (benefit) for income taxes		4,091			(1,283	)		5,374

Net income (loss)	$	8,118		$	(4,966	)	$	13,084


Basic earnings (loss) per share	$	0.25			(0.16	)	$	0.41
Diluted earnings (loss) per share	$	0.25			(0.15	)	$	0.40

Weighted average shares outstanding - Basic		31,902			31,902			31,902
Weighted average shares outstanding - Diluted		32,423			32,423			32,423

(a)

As previously reported in SEC filings prior to July 2018.

Page 15 of 39

STATEMENT OF CONTINUING OPERATIONS

GAAP TONON-GAAP RECONCILIATION

2017 Q1


	GAAP		Adjustments																						Non-GAAP

	Continuing Operations		LSA adjustment			Amortization of intangibles			IP related litigation				Consolidation and optimization			Acquisition and integration			Asset dispositions, severance and other			Debt / investment related charges			Adjusted Continuing Operations

Sales	$	266,736	$	(1,480	)	$	-		$	-			$	-		$	-		$	-		$	-		$	265,256
Cost of sales		184,708		1,675			(3,735	)		-				-			-			-			-			182,648

Gross profit (loss)		82,028		(3,155	)		3,735			-				-			-			-			-			82,608
Gross margin		31%		-1%			1%			0%				0%			0%			0%			0%			31%
Operating expenses:
Selling, general and administrative		34,794		-			(6,212	)		(377	)			-			-			-			-			28,205
SG&A as a % of sales		13%		0%			-2%			0%				0%			0%			0%			0%			11%
Research, development and engineering		11,637		-			(136	)		-				-			-			-			-			11,501
RD&E as a % of sales		4%		0%			0%			0%				0%			0%			0%			0%			4%
Other operating expenses		11,694		-			-			-				(2,347	)		(4,820	)		(4,527	)		-			-

Total operating expenses		58,125		-			(6,348	)		(377	)			(2,347	)		(4,820	)		(4,527	)		-			39,706
Operating income (loss)		23,903		(3,155	)		10,083			377				2,347			4,820			4,527			-			42,902
Operating margin		9%		-1%			4%			0%				1%			2%			2%			0%			16%
Interest expense		18,367		-			-			-				-			-			-			(1,559	)		16,808
Loss (gain) on cost and equity investments, net		398		-			-			-				-			-			-			(398	)		-
Other loss, net		1,401		-			-			-		��		-			-			-			-			1,401

Income (loss) before taxes		3,737		(3,155	)		10,083			377				2,347			4,820			4,527			1,957			24,693
Provision (benefit) for income taxes		789		(1,104	)		3,065			132				480			1,687			1,599			685			7,333
Effective tax rate		21%		35%			30%			35%				20%			35%			35%			35%			30%

Net income (loss)	$	2,948	$	(2,051	)	$	7,018		$	245			$	1,867		$	3,133		$	2,928		$	1,272		$	17,360


Diluted earnings (loss) per share	$	0.09	$	(0.06	)	$	0.22		$	0.01			$	0.06		$	0.10		$	0.09		$	0.04		$	0.55

Weighted average shares - Diluted		31,685		31,685			31,685			31,685				31,685			31,685			31,685			31,685			31,685

Page 16 of 39

STATEMENT OF CONTINUING OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

2017 Q2


	GAAP		Adjustments																					Non-GAAP
	Continuing Operations		LSA adjustment			Amortization of intangibles			IP related litigation			Consolidation and optimization			Acquisition and integration			Asset dispositions, severance and other			Debt / investment related charges			Adjusted Continuing Operations

Sales	$	280,916	$	(674	)	$	-		$	-		$	-		$	-		$	-		$	-		$	280,242
Cost of sales		191,741		2,082			(3,761	)		-			-			-			-			-			190,062
Gross profit (loss)		89,175		(2,756	)		3,761			-			-			-			-			-			90,180
Gross margin		32%		-1%			1%			0%			0%			0%			0%			0%			32%
Operating expenses:
Selling, general and administrative		35,146		-			(6,250	)		(915	)		-			-			-			-			27,981
SG&A as a % of sales		13%		0%			-2%			0%			0%			0%			0%			0%			10%
Research, development and engineering		11,240		-			(136	)		-			-			-			-			-			11,104
RD&E as a % of sales		4%		0%			0%			0%			0%			0%			0%			0%			4%
Other operating expenses		6,727		-			-			-			(2,729	)		(2,970	)		(1,028	)		-			-
Total operating expenses		53,113		-			(6,386	)		(915	)		(2,729	)		(2,970	)		(1,028	)		-			39,085
Operating income (loss)		36,062		(2,756	)		10,147			915			2,729			2,970			1,028			-			51,095
Operating margin		13%		-1%			4%			0%			1%			1%			0%			0%			18%
Interest expense		15,058		-			-			-			-			-			-			(935	)		14,123
Loss (gain) on cost and equity investments, net		4,427		-			-			-			-			-		��	-			(4,427	)		-
Other loss, net		6,763		-			-			-			-			-			-			-			6,763
Income (loss) before taxes		9,814		(2,756	)		10,147			915			2,729			2,970			1,028			5,362			30,209
Provision (benefit) for income taxes		255		(965	)		3,063			320			701			933			358			1,877			6,542
Effective tax rate		3%		35%			30%			35%			26%			31%			35%			35%			22%
Net income (loss)	$	9,559	$	(1,791	)	$	7,084		$	595		$	2,028		$	2,037		$	670		$	3,485		$	23,667


Diluted earnings (loss) per share	$	0.30	$	(0.06	)	$	0.22		$	0.02		$	0.06		$	0.06		$	0.02		$	0.11		$	0.74

Weighted average shares - Diluted		31,982		31,982			31,982			31,982			31,982			31,982			31,982			31,982			31,982

Page 17 of 39

STATEMENT OF CONTINUING OPERATIONS

GAAP TONON-GAAP RECONCILIATION

2017 Q3


	GAAP			Adjustments																					Non-GAAP
	Continuing Operations			LSA adjustment			Amortization of intangibles			IP related litigation			Consolidation and optimization			Acquisition and integration			Asset dispositions, severance and other			Debt / investment related charges			Adjusted Continuing Operations

Sales	$	286,168		$	(1,604	)	$	-		$	-		$	-		$	-		$	-		$	-		$	284,564
Cost of sales		196,982			1,846			(3,786	)		-			-			-			-			-			195,042
Gross profit (loss)		89,186			(3,450	)		3,786			-			-			-			-			-			89,522
Gross margin		31%			-1%			1%			0%			0%			0%			0%			0%			31%
Operating expenses:
Selling, general and administrative		35,064			-			(6,222	)		(1,735	)		-			-			-			-			27,107
SG&A as a % of sales		12%			0%			-2%			-1%			0%			0%			0%			0%			10%
Research, development and engineering		12,227			-			(137	)		-			-			-			-			-			12,090
RD&E as a % of sales		4%			0%			0%			0%			0%			0%			0%			0%			4%
Other operating expenses		6,069			-			-			-			(2,979	)		(2,267	)		(823	)		-			-
Total operating expenses		53,360			-			(6,359	)		(1,735	)		(2,979	)		(2,267	)		(823	)		-			39,197
Operating income (loss)		35,826			(3,450	)		10,145			1,735			2,979			2,267			823			-			50,325
Operating margin		13%			-1%			4%			1%			1%			1%			0%			0%			18%
Interest expense		15,808			-			-			-			-			-			-			(778	)		15,030
Loss (gain) on cost and equity investments, net		(1,906	)		-			-			-			-			-			-			1,906			-
Other loss, net		2,490			-			-			-			-			-			-			-			2,490
Income (loss) before taxes		19,434			(3,450	)		10,145			1,735			2,979			2,267			823			(1,128	)		32,805
Provision (benefit) for income taxes		(448	)		(1,208	)		3,042			607			349			1,161			277			(395	)		3,385
Effective tax rate		-2%			35%			30%			35%			12%			51%			34%			35%			10%
Net income (loss)	$	19,882		$	(2,242	)	$	7,103		$	1,128		$	2,630		$	1,106		$	546		$	(733	)	$	29,420


Diluted earnings (loss) per share	$	0.62		$	(0.07	)	$	0.22		$	0.04		$	0.08		$	0.03		$	0.02		$	(0.02	)	$	0.91

Weighted average shares - Diluted		32,173			32,173			32,173			32,173			32,173			32,173			32,173			32,173			32,173

Page 18 of 39

STATEMENT OF CONTINUING OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

2017 Q4


	GAAP			Adjustments																											Non-GAAP
	Continuing Operations			LSA adjustment			Amortization of intangibles			IP related litigation			Strategic reorganization and alignment			Consolidation and optimization			Acquisition and integration			Asset dispositions, severance and other			Debt / investment related charges			Tax Adjustment			Adjusted Continuing Operations

Sales	$	302,260		$	(1,568	)	$	-		$	-		$	-		$	-		$	-		$	-		$	-		$	-		$	300,692
Cost of sales		208,639			2,043			(3,901	)		-			-			-			-			-			-			-			206,781
Gross profit (loss)		93,621			(3,611	)		3,901			-			-			-			-			-			-			-			93,911
Gross margin		31%			-1%			1%			0%			0%			0%			0%			0%			0%			0%			31%
Operating expenses:
Selling, general and administrative		38,069			-			(6,156	)		(1,348	)		-			-			-			-			-			-			30,565
SG&A as a % of sales		13%			0%			-2%			0%			0%			0%			0%			0%			0%			0%			10%
Research, development and engineering		13,746			-			(136	)		-			-			-			-			-			-			-			13,610
RD&E as a % of sales		5%			0%			0%			0%			0%			0%			0%			0%			0%			0%			5%
Other operating expenses		11,948			-			-			-			(5,891	)		(4,880	)		(813	)		(364	)		-			-			-
Total operating expenses		63,763			-			(6,292	)		(1,348	)		(5,891	)		(4,880	)		(813	)		(364	)		-			-			44,175
Operating income (loss)		29,858			(3,611	)		10,193			1,348			5,891			4,880			813			364			-			-			49,736
Operating margin		10%			-1%			3%			0%			2%			2%			0%			0%			0%			0%			17%
Interest expense		14,739			-			-			-			-			-			-			-			(252	)		-			14,487
Loss (gain) on cost and equity investments, net		(1,354	)		-			-			-			-			-			-			-			1,354			-			-
Other loss, net		199			-			-			-			-			-			-			-			-			-			199
Income (loss) before taxes		16,274			(3,611	)		10,193			1,348			5,891			4,880			813			364			(1,102	)		-			35,050
Provision (benefit) for income taxes		(38,424	)		(1,264	)		3,076			472			2,062			1,147			(113	)		8			(386	)		39,806			6,384
Effective tax rate		-236%			35%			30%			35%			0%			24%			-14%			2%			35%						18%
Net income (loss)	$	54,698		$	(2,347	)	$	7,117		$	876		$	3,829		$	3,733		$	926		$	356		$	(716	)	$	(39,806	)	$	28,666


Diluted earnings (loss) per share	$	1.69		$	(0.07	)	$	0.22		$	0.03		$	0.12		$	0.12		$	0.03		$	0.01		$	(0.02	)	$	(1.23	)	$	0.89

Weighted average shares - Diluted		32,383			32,383			32,383			32,383			32,383			32,383			32,383			32,383			32,383			32,383			32,383

Page 19 of 39

STATEMENT OF CONTINUING OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

2017 FISCAL YEAR


	GAAP			Adjustments																											Non-GAAP
	Continuing Operations			LSA adjustment			Amortization of intangibles			IP related litigation			Strategic reorganization and alignment			Consolidation and optimization			Acquisition and integration			Asset dispositions, severance and other			Debt / investment related charges			Tax Adjustment			Adjusted Continuing Operations

Sales	$	1,136,080		$	(5,326	)	$	-		$	-		$	-		$	-		$	-		$	-		$	-		$	-		$	1,130,754
Cost of sales		782,070			7,646			(15,183	)		-			-			-			-			-			-			-			774,533
Gross profit (loss)		354,010			(12,972	)		15,183			-			-			-			-			-			-			-			356,221
Gross margin		31%			-1%			1%			0%			0%			0%			0%			0%			0%			0%			32%
Operating expenses:
Selling, general and administrative		143,073			-			(24,840	)		(4,375	)		-			-			-			-			-			-			113,858
SG&A as a % of sales		13%			0%			-2%			0%			0%			0%			0%			0%			0%			0%			10%
Research, development and engineering		48,850			-			(545	)		-			-			-			-			-			-			-			48,305
RD&E as a % of sales		4%			0%			0%			0%			0%			0%			0%			0%			0%			0%			4%
Other operating expenses		36,438			-			-			-			(5,891	)		(12,803	)		(10,870	)		(6,874	)		-			-			-
Total operating expenses		228,361			-			(25,385	)		(4,375	)		(5,891	)		(12,803	)		(10,870	)		(6,874	)		-			-			162,163
Operating income (loss)		125,649			(12,972	)		40,568			4,375			5,891			12,803			10,870			6,874			-			-			194,058
Operating margin		11%			-1%			4%			0%			1%			1%			1%			1%			0%			0%			17%
Interest expense		63,972			-			-			-			-			-			-			-			(3,524	)		-			60,448
Loss (gain) on cost and equity investments, net		1,565			-			-			-			-			-			-			-			(1,565	)		-			-
Other loss, net		10,853			-			-			-			-			-			-			-			-			-			10,853
Income (loss) before taxes		49,259			(12,972	)		40,568			4,375			5,891			12,803			10,870			6,874			5,089			-			122,757
Provision (benefit) for income taxes		(37,828	)		(4,541	)		12,246			1,531			2,062			2,545			3,668			2,374			1,781			39,806			23,644
Effective tax rate		-77%			35%			30%			35%			0%			20%			34%			35%			35%						19%
Net income (loss)	$	87,087		$	(8,431	)	$	28,322		$	2,844		$	3,829		$	10,258		$	7,202		$	4,500		$	3,308		$	(39,806	)	$	99,113


Diluted earnings (loss) per share	$	2.72		$	(0.26	)	$	0.88		$	0.09		$	0.12		$	0.32		$	0.22		$	0.14		$	0.10		$	(1.24	)	$	3.09

Weighted average shares - Diluted		32,056			32,056			32,056			32,056			32,056			32,056			32,056			32,056			32,056			32,056			32,056

Page 20 of 39

STATEMENT OF CONTINUING OPERATIONS

GAAP TO NON-GAAP RECONCILIATION

2018 Q1


	GAAP			Adjustments																											Non-GAAP
	Continuing Operations			LSA adjustment			Amortization of intangibles			IP related litigation			Strategic reorganization and alignment			Manufacturing alignment to support growth			Consolidation and optimization			Asset dispositions, severance and other			Debt / investment related charges			Tax Adjustment			Adjusted Continuing Operations

Sales	$	292,426		$	(695	)	$	-		$	-		$	-		$	-		$	-		$	-		$	-		$	-		$	291,731
Cost of sales		208,894			2,141			(3,716	)		-			-			-			-			-			-			-			207,319
Gross profit (loss)		83,532			(2,836	)		3,716			-			-			-			-			-			-			-			84,412
Gross margin		29%			-1%			1%			0%			0%			0%			0%			0%			0%			0%			29%
Operating expenses:
Selling, general and administrative		36,429			-			(6,898	)		(321	)		-			-			-			-			-			-			29,210
SG&A as a % of sales		12%			0%			-2%			0%			0%			0%			0%			0%			0%			0%			10%
Research, development and engineering		13,276			-			(39	)		-			-			-			-			-			-			-			13,237
RD&E as a % of sales		5%			0%			0%			0%			0%			0%			0%			0%			0%			0%			5%
Other operating expenses		3,784			-			-			-			(2,054	)		(513	)		(575	)		(642	)		-			-			-
Total operating expenses		53,489			-			(6,937	)		(321	)		(2,054	)		(513	)		(575	)		(642	)		-			-			42,447
Operating income (loss)		30,043			(2,836	)		10,653			321			2,054			513			575			642			-			-			41,965
Operating margin		10%			-1%			4%			0%			1%			0%			0%			0%			0%			0%			14%
Interest expense		15,595			-			-			-			-			-			-			-			(1,057	)		-			14,538
Loss (gain) on cost and equity investments, net		(4,970	)		-			-			-			-			-			-			-			4,970			-			-
Other loss, net		960			-			-			-			-			-			-			-			-			-			960
Income (loss) before taxes		18,458			(2,836	)		10,653			321			2,054			513			575			642			(3,913	)		-			26,467
Provision (benefit) for income taxes		5,374			(596	)		2,256			67			427			144			120			172			(822	)		(1,094	)		6,048
Effective tax rate		29%			21%			21%			21%			0%			0%			21%			27%			21%						23%
Net income (loss)	$	13,084		$	(2,240	)	$	8,397		$	254		$	1,627		$	369		$	455		$	470		$	(3,091	)	$	1,094		$	20,419


Diluted earnings (loss) per share	$	0.40		$	(0.07	)	$	0.26		$	0.01		$	0.05		$	0.01		$	0.01		$	0.01		$	(0.10	)	$	0.03		$	0.63

Weighted average shares - Diluted		32,423			32,423			32,423			32,423			32,423			32,423			32,423			32,423			32,423			32,423			32,423

Page 21 of 39

SALES

GAAP TO NON-GAAP RECONCILIATION

2017 Q1


	GAAP									NON-GAAP

	(a)		LESS:							Adjusted
	Total		Discontinued		Continuing					Continuing
	Operations		Operations		Operations		Adjustments			Operations

Medical
Cardio & Vascular	$	125,108	$	1,624	$	123,484	$	2	(b)	$	123,486
Cardiac & Neuromodulation		103,813		58		103,755		(2)	(b)		103,753
Advanced Surgical, Orthopedics & Portable Medical		105,146		76,995		28,151		(1,480)	(b)		26,671

Total Medical		334,067		78,677		255,390		(1,480)			253,910
Non-Medical		11,346		-		11,346		-			11,346

Total sales	$	345,413	$	78,677	$	266,736	$	(1,480)		$	265,256

(a)

As previously reported in SEC filings prior to July 2018.

(b)

Net impact of LSA agreement.

Page 22 of 39

SALES

GAAP TO NON-GAAP RECONCILIATION

2017 Q2


	GAAP									NON-GAAP

	(a)		LESS:							Adjusted
	Total		Discontinued		Continuing					Continuing
	Operations		Operations		Operations		Adjustments			Operations

Medical
Cardio & Vascular	$	132,231	$	1,513	$	130,718	$	(1)	(b)	$	130,717
Cardiac & Neuromodulation		106,185		12		106,173		-	(b)		106,173
Advanced Surgical, Orthopedics & Portable Medical		108,560		80,278		28,282		(673)	(b)		27,609

Total Medical		346,976		81,803		265,173		(674)			264,499
Non-Medical		15,743		-		15,743		-			15,743

Total sales	$	362,719	$	81,803	$	280,916	$	(674)		$	280,242

(a)

As previously reported in SEC filings prior to July 2018.

(b)

Net impact of LSA agreement.

Page 23 of 39

SALES

GAAP TO NON-GAAP RECONCILIATION

2017 Q3


	GAAP									NON-GAAP

	(a)		LESS:							Adjusted
	Total		Discontinued		Continuing					Continuing
	Operations		Operations		Operations		Adjustments			Operations

Medical
Cardio & Vascular	$	138,982	$	1,270	$	137,712	$	(16)	(b)	$	137,696
Cardiac & Neuromodulation		101,616		4		101,612		-	(b)		101,612
Advanced Surgical, Orthopedics & Portable Medical		107,581		75,866		31,715		(1,588)	(b)		30,127

Total Medical		348,179		77,140		271,039		(1,604)			269,435
Non-Medical		15,129		-		15,129		-			15,129

Total sales	$	363,308	$	77,140	$	286,168	$	(1,604)		$	284,564

(a)

As previously reported in SEC filings prior to July 2018.

(b)

Net impact of LSA agreement.

Page 24 of 39

SALES

GAAP TO NON-GAAP RECONCILIATION

2017 Q4


	GAAP									NON-GAAP

	(a)		LESS:							Adjusted
	Total		Discontinued		Continuing					Continuing
	Operations		Operations		Operations		Adjustments			Operations

Medical
Cardio & Vascular	$	140,473	$	1,556	$	138,917	$	(12)	(b)	$	138,905
Cardiac & Neuromodulation		116,735		-		116,735		-	(b)		116,735
Advanced Surgical, Orthopedics & Portable Medical		118,523		86,665		31,858		(1,556)	(b)		30,302

Total Medical		375,731		88,221		287,510		(1,568)			285,942
Non-Medical		14,750		-		14,750		-			14,750

Total sales	$	390,481	$	88,221	$	302,260	$	(1,568)		$	300,692

(a)

As previously reported in SEC filings prior to July 2018.

(b)

Net impact of LSA agreement.

Page 25 of 39

SALES

GAAP TO NON-GAAP RECONCILIATION

2017 FISCAL YEAR


	GAAP									NON-GAAP

	(a)		LESS:							Adjusted
	Total		Discontinued		Continuing					Continuing
	Operations		Operations		Operations		Adjustments			Operations

Medical
Cardio & Vascular	$	536,794	$	5,963	$	530,831	$	(27)	(b)	$	530,804
Cardiac & Neuromodulation		428,349		74		428,275		(2)	(b)		428,273
Advanced Surgical, Orthopedics & Portable Medical		439,810		319,804		120,006		(5,297)	(b)		114,709

Total Medical		1,404,953		325,841		1,079,112		(5,326)			1,073,786
Non-Medical		56,968		-		56,968		-			56,968

Total sales	$	1,461,921	$	325,841	$	1,136,080	$	(5,326)		$	1,130,754

(a)

As previously reported in SEC filings prior to July 2018.

(b)

Net impact of LSA agreement.

Page 26 of 39

SALES

GAAP TO NON-GAAP RECONCILIATION

2018 Q1


	GAAP									NON-GAAP

	(a)		LESS:							Adjusted
	Total		Discontinued		Continuing					Continuing
	Operations		Operations		Operations		Adjustments			Operations

Medical
Cardio & Vascular	$	138,348	$	1,485	$	136,863	$	(11)	(b)	$	136,852
Cardiac & Neuromodulation		108,910		-		108,910		-	(b)		108,910
Advanced Surgical, Orthopedics & Portable Medical		121,775		87,834		33,941		(684)	(b)		33,257

Total Medical		369,033		89,319		279,714		(695)			279,019
Non-Medical		12,712		-		12,712		-			12,712

Total sales	$	381,745	$	89,319	$	292,426	$	(695)		$	291,731

(a)

As previously reported in SEC filings prior to July 2018.

(b)

Net impact of LSA agreement.

Page 27 of 39

NET INCOME

GAAP TO NON-GAAP RECONCILIATION

2017 Q1


	(a)			LESS:
	Total			Discontinued			Continuing
Net Income (Loss) Reconciliation *	Operations			Operations			Operations

Net income (loss) (GAAP)	$	(4,339	)	$	(7,287	)	$	2,948
Adjustments:
Amortization of intangibles		7,746			728			7,018
Depreciation on held for sale assets		-			-			-
IP related litigation (SG&A)		245			-			245
Strategic reorganization and alignment (OOE)		-			-			-
Manufacturing alignment to support growth (OOE)		-			-			-
Consolidation and optimization expenses (OOE)		1,899			32			1,867
Acquisition and integration expenses (OOE)		3,133			-			3,133
Asset dispositions, severance and other (OOE)		2,957			29			2,928
Loss on cost/equity method investments		259			-			259
Loss on extinguishment of debt		1,013			-			1,013
LSA adjustments		-			2,051			(2,051	)
Tax adjustments		-			-			-

Adjusted net income (loss)(Non-GAAP)	$	12,913		$	(4,447	)	$	17,360


Diluted earnings (loss) per share	$	0.41		$	(0.14	)	$	0.55

Weighted average shares outstanding - Diluted		31,685			31,685			31,685

(a)

As previously reported in SEC filings prior to July 2018.

*	Amounts shown are net of tax.

Page 28 of 39

NET INCOME

GAAP TO NON-GAAP RECONCILIATION

2017 Q2


	(a)		LESS:
	Total		Discontinued			Continuing
Net Income (Loss) Reconciliation *	Operations		Operations			Operations

Net income (loss) (GAAP)	$	2,990	$	(6,569	)	$	9,559
Adjustments:
Amortization of intangibles		7,815		731			7,084
Depreciation on held for sale assets		-		-			-
IP related litigation (SG&A)		595		-			595
Strategic reorganization and alignment (OOE)		-		-			-
Manufacturing alignment to support growth (OOE)		-		-			-
Consolidation and optimization expenses (OOE)		2,093		65			2,028
Acquisition and integration expenses (OOE)		2,037		-			2,037
Asset dispositions, severance and other (OOE)		727		57			670
Loss on cost/equity method investments		2,877		-			2,877
Loss on extinguishment of debt		608		-			608
LSA adjustments		-		1,791			(1,791	)
Tax adjustments		-		-			-

Adjusted net income (loss)(Non-GAAP)	$	19,742	$	(3,925	)	$	23,667


Diluted earnings (loss) per share	$	0.62	$	(0.12	)	$	0.74

Weighted average shares outstanding - Diluted		31,982		31,982			31,982

(a)

As previously reported in SEC filings prior to July 2018.

*	Amounts shown are net of tax.

Page 29 of 39

NET INCOME

GAAP TO NON-GAAP RECONCILIATION

2017 Q3


	(a)			LESS:
	Total			Discontinued			Continuing
Net Income (Loss) Reconciliation *	Operations			Operations			Operations

Net income (loss) (GAAP)	$	13,690		$	(6,192	)	$	19,882
Adjustments:
Amortization of intangibles		7,840			737			7,103
Depreciation on held for sale assets		-			-			-
IP related litigation (SG&A)		1,128			-			1,128
Strategic reorganization and alignment (OOE)		-			-			-
Manufacturing alignment to support growth (OOE)		-			-			-
Consolidation and optimization expenses (OOE)		2,737			107			2,630
Acquisition and integration expenses (OOE)		1,106			-			1,106
Asset dispositions, severance and other (OOE)		563			17			546
Gain on cost/equity method investments		(1,239	)		-			(1,239	)
Loss on extinguishment of debt		506			-			506
LSA adjustments		-			2,242			(2,242	)
Tax adjustments		-			-			-

Adjusted net income (loss)(Non-GAAP)	$	26,331		$	(3,089	)	$	29,420


Diluted earnings (loss) per share	$	0.82		$	(0.10	)	$	0.91

Weighted average shares outstanding - Diluted		32,173			32,173			32,173

(a)

As previously reported in SEC filings prior to July 2018.

*	Amounts shown are net of tax.

Page 30 of 39

NET INCOME

GAAP TO NON-GAAP RECONCILIATION

2017 Q4


	(a)			LESS:
	Total			Discontinued			Continuing
Net Income (Loss) Reconciliation *	Operations			Operations			Operations

Net income (loss) (GAAP)	$	54,338		$	(360	)	$	54,698
Adjustments:
Amortization of intangibles		7,854			737			7,117
Depreciation on held for sale assets		-			-			-
IP related litigation (SG&A)		876			-			876
Strategic reorganization and alignment (OOE)		3,829			-			3,829
Manufacturing alignment to support growth (OOE)		-			-			-
Consolidation and optimization expenses (OOE)		3,886			153			3,733
Acquisition and integration expenses (OOE)		926			-			926
Asset dispositions, severance and other (OOE)		475			119			356
Gain on cost/equity method investments		(880	)		-			(880	)
Loss on extinguishment of debt		164			-			164
LSA adjustments		-			2,347			(2,347	)
Tax adjustments		(40,281	)		(475	)		(39,806	)

Adjusted net income (loss)(Non-GAAP)	$	31,187		$	2,521		$	28,666


Diluted earnings (loss) per share	$	0.96		$	0.08		$	0.89

Weighted average shares outstanding - Diluted		32,383			32,383			32,383

(a)

As previously reported in SEC filings prior to July 2018.

*	Amounts shown are net of tax.

Page 31 of 39

NET INCOME

GAAP TO NON-GAAP RECONCILIATION

2017 FISCAL YEAR


Net Income (Loss) Reconciliation *	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Net income (loss) (GAAP)	$	66,679		$	(20,408	)	$	87,087
Adjustments:
Amortization of intangibles		31,255			2,933			28,322
Depreciation on held for sale assets		-			-			-
IP related litigation (SG&A)		2,844			-			2,844
Strategic reorganization and alignment (OOE)		3,829			-			3,829
Manufacturing alignment to support growth (OOE)		-			-			-
Consolidation and optimization expenses (OOE)		10,615			357			10,258
Acquisition and integration expenses (OOE)		7,202			-			7,202
Asset dispositions, severance and other (OOE)		4,722			222			4,500
Loss on cost/equity method investments		1,017			-			1,017
Loss on extinguishment of debt		2,291			-			2,291
LSA adjustments		-			8,431			(8,431	)
Tax adjustments		(40,281	)		(475	)		(39,806	)

Adjusted net income (loss)(Non-GAAP)	$	90,173		$	(8,940	)	$	99,113


Diluted earnings (loss) per share	$	2.81		$	(0.28	)	$	3.09

Weighted average shares outstanding - Diluted		32,056			32,056			32,056

(a)

As previously reported in SEC filings prior to July 2018.

*	Amounts shown are net of tax.

Page 32 of 39

NET INCOME

GAAP TO NON-GAAP RECONCILIATION

2018 Q1


Net Income (Loss) Reconciliation *	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Net income (loss) (GAAP)	$	8,118		$	(4,966	)	$	13,084
Adjustments:
Amortization of intangibles		9,304			907			8,397
Depreciation on held for sale assets		-			-			-
IP related litigation (SG&A)		254			-			254
Strategic reorganization and alignment (OOE)		2,779			1,152			1,627
Manufacturing alignment to support growth (OOE)		369			-			369
Consolidation and optimization expenses (OOE)		473			18			455
Acquisition and integration expenses (OOE)		-			-			-
Asset dispositions, severance and other (OOE)		489			19			470
Gain on cost/equity method investments		(3,926	)		-			(3,926	)
Loss on extinguishment of debt		835			-			835
LSA adjustments		-			2,240			(2,240	)
Tax adjustments		1,021			(73	)		1,094

Adjusted net income (loss)(Non-GAAP)	$	19,716		$	(703	)	$	20,419


Diluted earnings (loss) per share	$	0.61		$	(0.02	)	$	0.63

Weighted average shares outstanding - Diluted		32,423			32,423			32,423

(a)

As previously reported in SEC filings prior to July 2018.

*	Amounts shown are net of tax.

Page 33 of 39

EBITDA

GAAP TO NON-GAAP RECONCILIATION

2017 Q1


*EBITDA and Adjusted EBITDA Reconciliation*	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Net income (loss) (GAAP)	$	(4,339	)	$	(7,287	)	$	2,948
Adjustments:
Interest expense		28,893			10,526			18,367
Provision (benefit) for income taxes		144			(645	)		789
Depreciation		13,628			4,258			9,370
Amortization		10,978			895			10,083

EBITDA		49,304			7,747			41,557
IP related litigation		377			-			377
Stock-based compensation (excluding OOE)		2,406			233			2,173
Strategic reorganization and alignment		-			-			-
Manufacturing alignment to support growth		-			-			-
Consolidation and optimization expenses		2,395			48			2,347
Acquisition and integration expenses		4,820			-			4,820
Asset dispositions, severance and other		4,556			29			4,527
Non-cash loss on cost/equity method investments		398			-			398
LSA adjustments		-			3,155			(3,155	)

Adjusted EBITDA(Non-GAAP)	$	64,256		$	11,212		$	53,044

(a)

As previously reported in SEC filings prior to July 2018.

Page 34 of 39

EBITDA

GAAP TO NON-GAAP RECONCILIATION

2017 Q2


*EBITDA and Adjusted EBITDA Reconciliation*	(a) Total Operations		LESS: Discontinued Operations			Continuing Operations

Net income (loss) (GAAP)	$	2,990	$	(6,569	)	$	9,559
Adjustments:
Interest expense		25,647		10,589			15,058
Provision for income taxes		1,126		871			255
Depreciation		13,813		4,455			9,358
Amortization		11,046		899			10,147

EBITDA		54,622		10,245			44,377
IP related litigation		915		-			915
Stock-based compensation (excluding OOE)		3,251		349			2,902
Strategic reorganization and alignment		-		-			-
Manufacturing alignment to support growth		-		-			-
Consolidation and optimization expenses		2,832		103			2,729
Acquisition and integration expenses		2,970		-			2,970
Asset dispositions, severance and other		1,118		90			1,028
Non-cash loss on cost/equity method investments		4,427		-			4,427
LSA adjustments		-		2,756			(2,756	)

Adjusted EBITDA(Non-GAAP)	$	70,135	$	13,543		$	56,592

(a)

As previously reported in SEC filings prior to July 2018.

Page 35 of 39

EBITDA

GAAP TO NON-GAAP RECONCILIATION

2017 Q3


*EBITDA and Adjusted EBITDA Reconciliation*	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Net income (loss) (GAAP)	$	13,690		$	(6,192	)	$	19,882
Adjustments:
Interest expense		26,485			10,677			15,808
Benefit for income taxes		(1,700	)		(1,252	)		(448	)
Depreciation		14,068			4,534			9,534
Amortization		11,051			906			10,145

EBITDA		63,594			8,673			54,921
IP related litigation		1,735			-			1,735
Stock-based compensation (excluding OOE)		2,149			108			2,041
Strategic reorganization and alignment		-			-			-
Manufacturing alignment to support growth		-			-			-
Consolidation and optimization expenses		3,143			164			2,979
Acquisition and integration expenses		2,267			-			2,267
Asset dispositions, severance and other		854			31			823
Non-cash gain on cost/equity method investments		(992	)		-			(992	)
LSA adjustments		-			3,450			(3,450	)

Adjusted EBITDA(Non-GAAP)	$	72,750		$	12,426		$	60,324

(a)

As previously reported in SEC filings prior to July 2018.

Page 36 of 39

EBITDA

GAAP TO NON-GAAP RECONCILIATION

2017 Q4


*EBITDA and Adjusted EBITDA Reconciliation*	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Net income (loss) (GAAP)	$	54,338		$	(360	)	$	54,698
Adjustments:
Interest expense		25,435			10,696			14,739
Benefit for income taxes		(44,422	)		(5,998	)		(38,424	)
Depreciation		14,575			4,760			9,815
Amortization		11,099			906			10,193

EBITDA		61,025			10,004			51,021
IP related litigation		1,348			-			1,348
Stock-based compensation (excluding OOE)		4,618			451			4,167
Strategic reorganization and alignment		5,891			-			5,891
Manufacturing alignment to support growth		-			-			-
Consolidation and optimization expenses		5,111			231			4,880
Acquisition and integration expenses		813			-			813
Asset dispositions, severance and other		522			158			364
Non-cash gain on cost/equity method investments		(868	)		-			(868	)
LSA adjustments		-			3,611			(3,611	)

Adjusted EBITDA(Non-GAAP)	$	78,460		$	14,455		$	64,005

(a)

As previously reported in SEC filings prior to July 2018.

Page 37 of 39

EBITDA

GAAP TO NON-GAAP RECONCILIATION

2017 FISCAL YEAR


*EBITDA and Adjusted EBITDA Reconciliation*	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Net income (loss) (GAAP)	$	66,679		$	(20,408	)	$	87,087
Adjustments:
Interest expense		106,460			42,488			63,972
Benefit for income taxes		(44,852	)		(7,024	)		(37,828	)
Depreciation		56,084			18,007			38,077
Amortization		44,174			3,606			40,568

EBITDA		228,545			36,669			191,876
IP related litigation		4,375			-			4,375
Stock-based compensation (excluding OOE)		12,424			1,141			11,283
Strategic reorganization and alignment		5,891			-			5,891
Manufacturing alignment to support growth		-			-			-
Consolidation and optimization expenses		13,349			546			12,803
Acquisition and integration expenses		10,870			-			10,870
Asset dispositions, severance and other		7,182			308			6,874
Non-cash loss on cost/equity method investments		2,965			-			2,965
LSA adjustments		-			12,972			(12,972	)

Adjusted EBITDA(Non-GAAP)	$	285,601		$	51,636		$	233,965

(a)

As previously reported in SEC filings prior to July 2018.

Page 38 of 39

EBITDA

GAAP TO NON-GAAP RECONCILIATION

2018 Q1


*EBITDA and Adjusted EBITDA Reconciliation*	(a) Total Operations			LESS: Discontinued Operations			Continuing Operations

Net income (loss) (GAAP)	$	8,118		$	(4,966	)	$	13,084
Adjustments:
Interest expense		26,445			10,850			15,595
Provision (benefit) for income taxes		4,091			(1,283	)		5,374
Depreciation		14,621			4,658			9,963
Amortization		11,713			1,060			10,653

EBITDA		64,988			10,319			54,669
IP related litigation		321			-			321
Stock-based compensation (excluding OOE)		3,218			239			2,979
Strategic reorganization and alignment		3,492			1,438			2,054
Manufacturing alignment to support growth		513			-			513
Consolidation and optimization expenses		605			30			575
Acquisition and integration expenses		-			-			-
Asset dispositions, severance and other		667			25			642
Non-cash gain on cost/equity method investments		(4,970	)		-			(4,970	)
LSA adjustments		-			2,836			(2,836	)

Adjusted EBITDA(Non-GAAP)	$	68,834		$	14,887		$	53,947

(a)

As previously reported in SEC filings prior to July 2018.

Page 39 of 39

Integer (ITGR) 8-K2017 by Quarter and Total Year - 5 periods